ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,247.79
-0.41%
Dow Jones
39,112.16
-0.76%
Gold vs US Dollar
2,319.65
-0.48%
Brent Oil
84.075
-0.13%
Bitcoin
61,805.44
0.00%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ALX Oncology Holdings Inc (ALXO)

  7. ALX Oncology Holdings Inc (ALXO) News

ALX Oncology (ALXO)

ALX Oncology Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALXO
DateTimeSourceHeadlineSymbolCompany
17/06/202421:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALXOALX Oncology Holdings Inc
06/06/202421:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
04/06/202421:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
02/06/202415:00GlobeNewswire Inc.ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder CancerNASDAQ:ALXOALX Oncology Holdings Inc
29/05/202414:00GlobeNewswire Inc.ALX Oncology Announces Participation in the Jefferies Global Healthcare ConferenceNASDAQ:ALXOALX Oncology Holdings Inc
15/05/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
13/05/202421:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
09/05/202421:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALXOALX Oncology Holdings Inc
09/05/202421:00GlobeNewswire Inc.ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ALXOALX Oncology Holdings Inc
08/05/202422:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
07/05/202414:00GlobeNewswire Inc.ALX Oncology Appoints Allison Dillon as Chief Business OfficerNASDAQ:ALXOALX Oncology Holdings Inc
06/05/202421:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
30/04/202414:00GlobeNewswire Inc.ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal CancerNASDAQ:ALXOALX Oncology Holdings Inc
24/04/202415:00GlobeNewswire Inc.ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual MeetingNASDAQ:ALXOALX Oncology Holdings Inc
09/04/202422:30GlobeNewswire Inc.ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)NASDAQ:ALXOALX Oncology Holdings Inc
07/03/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALXOALX Oncology Holdings Inc
07/03/202421:03GlobeNewswire Inc.ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:ALXOALX Oncology Holdings Inc
05/03/202421:30GlobeNewswire Inc.ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual MeetingNASDAQ:ALXOALX Oncology Holdings Inc
16/02/202423:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
16/02/202423:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
16/02/202423:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
05/01/202421:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
03/01/202421:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
03/01/202421:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
03/01/202421:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALXOALX Oncology Holdings Inc
03/01/202413:00GlobeNewswire Inc.ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALXOALX Oncology Holdings Inc
26/12/202321:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALXOALX Oncology Holdings Inc
13/11/202321:05GlobeNewswire Inc.ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:ALXOALX Oncology Holdings Inc
13/11/202321:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALXOALX Oncology Holdings Inc
01/11/202320:05GlobeNewswire Inc.ALX Oncology Announces November Investor Conference ParticipationNASDAQ:ALXOALX Oncology Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:ALXO

Your Recent History

NASDAQ
RCM
R1 RCM
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved